Диссертация (1140617), страница 21
Текст из файла (страница 21)
Knopman D.S. Dementia and cerebrovascular disease. Mayo Clin Proc.2006;81:223-230.202. Knopman D.S., DeKosky S.T., Cummings J.L., et al. Practice parameter:diagnosis of dementia (an evidence-based review). Report of the Quality StandardsSubcommittee of the American Academy of Neurology.Neurology. May 82001;56(9):1143-53.203. Konno S., Meyer J.S., Terayama Y., et al. Classification, diagnosis and treatmentof vascular dementia. Drugs Aging. 1997 Nov;11(5):361-73.204. Lammie G.A. Hypertensive cerebral small vessel disease and stroke. BrainPathol (2002) 12: 358–370.205.
Lang A. E., Lozano A. M. Parkinson's disease. First of two parts. N Engl J Med339: 1044-53, 1998.206. Lanska D.J., Rembler B. Benign paroxysmal positioning vertigo: classicdescriptions, origins of the provocative positioning technique, and conceptualdevelopments. // Neurology.
1997; 48:1167-1177.207. Launer L.J., Masaki K., Petrovitch H. et al. The association between midlifeblood pressure levels and late-life cognitive function. The Honolulu-Asia AgingStudy. JAMA 1995;274:1846-51.208. Lee H.,Yi H. A., Baloh R. W. Sudden bilateral simultaneous deafness withvertigo as a sole manifestation of vertebrobasilar insufficiency. JNNP. 2003; 74: 539120541.209. Loane C., Politis M. Buspirone: what is it all about? Brain Res. 2012 Jun21;1461:111-8. doi: 10.1016/j.brainres.2012.04.032. Epub 2012 Apr 24.210.
Loeb C., Meyer J.S. Vascular Dementia: still a debatable entity? J Neurol Sci1996;143:31-40.211. Longstreth W.T., Manolio T.A., Arnold A., et al. Clinical correlates of whitematter findings on cranial magnetic resonance imaging of 3301 elderly people: theCardiovascular Health Study. Stroke. 1996;27:1274–1282.212. Lopez O.L., Becker J.T., Jagust W.J., et al. Neuropsychological characteristics ofmild cognitive impairment subgroups.
J Neurol Neurosurg Psychiatry. 2006;77:159–165.213. Lopez O.L., Larumbe M.R., Becker J.T., et al. Reliability of NINDS-AIRENcriteria for the diagnosis of vascular dementia. Neurology. 1994;44:1240–1245.214. Lopez O.L., Kuller L.H., Becker J.T., et al. Classification of vascular dementiain the Cardiovascular Health Study Cognition Study.
Neurology. 2005;64:1539–1547.215. Lyketsos C., Lopez O., Jones B., et al. Prevalence of neuropsychiatric symptomsin dementia and mild cognitive impairment, JAMA (2002) 288:1475-83.216. Manly J.J., Bell-McGinty S., Tang M.X., et al. Implementing diagnostic criteriaand estimating frequency of mild cognitive impairment in an urban community. ArchNeurol. 2005;62:1739–1746.217. Marcusson J., Rother M., Kittner B., et al, A 12-month randomized, placebocontrolled, trial of propentofylline (HWA285) in patients with dementia according toDSM-III-R, Dementia (1997) 8:320-8.218.
Mayberg H.S., Liotti M., Brannan S.K., et al. Reciprocal limbic-cortical functionand negative mood: converging PET findings in depression and normal sadness. Am JPsychiatry. May 1999;156(5):675-82.219. Mayer-Gross W., Slater E., Roth M. Ageing and the mental diseases of the aged;in Slater E., Roth M. (eds): Clinical Psychiatry, ed 3. London, Bailliere, Tindall &Carssell, 1969, pp 533–629.220.
McAllister TW, Neuropsychiatric sequale of head injures Psychiatric Clin N Am121(1992) 15:395-413.221. Medana I.M. and Esiri M.M. Axonal damage: a key predictor of outcome inhuman CNS diseases. Brain (2003) 126: 515–530.222. Mielke R., Moller H-J., Erkinjuntti T., et al, Propentofylline in the treatment ofvascular dementia and Alzheimer type dementia: overview of phase 1 and phase 2clinical trials, Alzheimer Dis Assoc Disord (1998); 12 (Suppl 2):S29-S35.223. Modrego P.J., Ferrandez J. Depression in patients with mild cognitiveimpairment increases the risk of developing dementia of Alzheimer type: aprospective cohort study. Arch Neurol. Aug 2004;61(8):1290-3.224.
Modrick M.L., Didion S.P., Sigmund C.D., Faraci F.M. Role of oxidative stressand AT1 receptors in cerebral vascular dysfunction with aging. Am J Physiol HeartCirc Physiol. 2009;296:H1914–H1919.225. Nagata K., Maruya H., Yuya H., et al. Can PET data differentiate Alzheimer'sdisease from vascular dementia? Ann N Y Acad Sci. Apr 2000;903:252-61.226. Neuhauser H.K., von Brevern M., Radtke A., et al. Epidemiology of vestibularvertigo: A neurotologic survey of the general population Neurology, Sep 2005; 65:898 - 904.227.
Niwa K., Carlson G.A., Iadecola C. Exogenous A beta1–40 reproducescerebrovascular alterations resulting from amyloid precursor protein overexpressionin mice. J Cereb Blood Flow Metab. 2000;20:1659–1668.228. Niwa K., Kazama K., Younkin L., et al. Cerebrovascular autoregulation isprofoundly impaired in mice overexpressing amyloid precursor protein. Am J PhysiolHeart Circ Physiol.2002;283:H315–H323.229. Niwa K., Porter V.A., Kazama K., et al. A beta-peptides enhancevasoconstriction in cerebral circulation.
Am J Physiol Heart Circ Physiol.2001;281:H2417–H2424.230. Noble S., Wagstaff A.J. Propentofylline, CNS Drugs (1997) 8:257-66.231. O'Brien J.T., Erkinjuntti T., Reisberg B., et al. Vascular cognitive impairment.Lancet Neurol. 2003 Feb;2(2):89-98.232.
Orgogozo J.M., Rigaud A.S., Stoffler A., et al, Efficacy and safety memantine in122patients with mild to moderate vascular dementia: a randomised, placebo-controlledtrial (MMM 300), Stroke (2002) 33:1834-9.233. Pagarkar W., Davies R. Dizziness. Medicine. 2004;32:18–23.234. Pantoni L., Garsia J.H. Pathogenesis of leukoaraiosis // Stroke. 1997. Vol.28. P.652-659.235. Panza F., Colacicci A.M. et al.
Cerebrovascular disease in the elderly:lipoprotein metabolism and cognitive decline. Aging Clin Exp Res 2006; 18:144-148.236. Park L., Anrather J., Girouard H., Zhou P., Iadecola C. Nox2-derived reactiveoxygen species mediate neurovascular dysregulation in the aging mouse brain. JCereb Blood Flow Metab. 2007;27:1908–1918.237. Parsons M.W., Barber P.A., Desmond P.M. et al. Acute hyperglycemia adverselyaffects stroke outcome: a magnetic resonanse imaging and spectroscopy study, AnnNeurol (2002) 52:20-8.238. Pfeifer L.A., White L.R., Ross G.W., Petrovitch H., Launer L.J.
Cerebralamyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology.2002;58:1629–1634.239. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mildcognitive impairment: clinical characterization and outcome [published correctionappears in Arch Neurol. 1999;56:760]. Arch Neurol. 1999;56:303–308.240. Petrovitch H., Ross G.W., Steinhorn S.C., et al. AD lesions and infarcts indemented and non-demented Japanese-American men. Ann Neurol. 2005;57:98–103.241. Poeck K, Hacke W, Neurologie.
Berlin: Springer Verlag. 2006. S. 173-79.242. Pohjasvaara T., Mäntylä R., Ylikoski R., et al. Comparison of different clinicalcriteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis ofvascular dementia. National Institute of Neurological Disorders and StrokeAssociation Internationale pour la Recherche et l'Enseignement en Neurosciences.Stroke. 2000 Dec; 31(12):2952-7.243. Posatirelin for the treatment of degenerative and vascular dementia: results ofexplanatory and pragmatic efficacy analyses.
Arch Gerontol Geriatr. 1998 JanFeb;26(1):33-47.123244. Post F. The significance of Affective symptoms in Old Age. A Follow-up of OneHundred Patients. London: Oxford University Press: London, 1962.245. Rao R. Cerebrovascular disease and late life depression: an age old associationrevisited, Int J Geriat Psychiatry (2000) 15:419-33.246. Rasmussen B.K.
Epidemiology of migraine // Towards Migraine 2000 / F.Clifford Rose (ed.) Elsevier Science. 1996. P. 1-15.247. Rasmussen B.K., Olesen J. Epidemiology of migraine and tension-typeheadache. Curr Opin Neurol. Jun 1994;7(3):264-71.248. Robertson J.T., Current management of vertebral basilar occlusive disease.
ClinNeurosurg 31: 165-87, 1983.249. Rockwood K. Vascular cognitive impairment and vascular dementia, J NeurolSci (2002) 203-4:23-7.250. Rodgers A., MacMahon S., Gamble G. et al. Blood pressure and risk of stroke inpatients with cerebrovascular disease. The United Kingdom Transient Ishemic AttackCollobrative Group, BMJ (1996) 313:147.251. Roman G.C. Vascular dementia: NINDS - AIREN diagnostic criteria. //In: Newconcepts in vascular dementia. A.Culebras, J.Matias Guiu, G.Roman (eds).Barcelona: Prous Science Publishers. -1993. -P.1-9.252. Roman G.C. Vascular dementia prevention: a risk for analysis. Cerebrovas Dis2005:20 (Supll 2):91-100.253. Roman G.C., Tatemichi T.K., Erkinjuntti T., et al, Vascular dementia: Diagnosticcriteria for research studies. Report of the NINDS-AIREN International workshop.
JNeurol 1993; 43:250-260.254. Ross R. The pathogenesis of atherosclerosis – An Update. N Eng J Med. 1986;314:488-500.255. Sacco R.L. Risk factors and outcomes for ischemic stroke // Neurology. – 1995.Vol. 45. – Suppl. 1. – P. 10-14.256. Sachdev P.S., Chen X., Brodaty H., Thompson C., Altendorf A., Wen W. Thedeterminants and longitudinal course of post-stroke mild cognitive impairment. J IntNeuropsychol Soc. 2009;15:915–923.124257. Sacher J., Neumann J., Funfstuck T., Soliman A., Villringer A., Schroeter M.L.Mapping the depressed brain: A meta-analysis of structural and functional alterationsin major depressive disorder. J Affect Disord.
Sep 2 2011.258. Savitz S.I., Caplan L.R. Vertebrobasilar Disease // N Engl J Med 2005;352:2618-2626.259. Scheiber S.S. The psychiatric interview, psychiatric history, and mental statusexamination. In: Hales R.E., Yudofsky S.C., eds. Essentials of Clinical Psychiatry.3rd ed. Washington, DC: American Psychiatric Press; 1999:55-86.260. Schneider J.A., Aggarwal N.T., Barnes L., Boyle P., Bennett D.A. Theneuropathology of older persons with and without dementia from community versusclinic cohorts. J Alzheimers Dis.
2009;18:691–701.261. Schneider J.A., Wilson R.S., Bienias J.L., et al. Cerebral infarctions and thelikelihood of dementia from Alzheimer disease pathology. Neurology. 2004;62:1148–1155.262. Selnes O. A., Vinters H. V. Vascular cognitive impairment. Nature ClinicalPractice // Neurology. 2006. Oct; Vol 2; № 10: 538-547.263. Skoog I., Lernfelt B., Landahl S. et al. 15-years longitudinal study of bloodpressure and dementia, Lancet (1996) 347:1141-5.264. Snowdon D.A., Grainer L.H., Mortimer J.A., Riley K.P., Grainer P.A.,Markesbery W.R. Brain infarction and the clinical expression of Alzheimer disease:the Nun Study. JAMA.
1997;277:813–817.265. Sonnen J.A., Larson E.B., Crane P.K., et al. Pathological correlates of dementiain a longitudinal, population-based sample of aging. Ann Neurol. 2007;62:406–413.266. Starkstein S.E., Sabe L., Vazquez S., et al. Neuropsychological, psychiatric, andcerebral blood flow findings in vascular dementia and Alzheimer's disease. Stroke.Mar 1996;27(3):408-14.267. Storper I.S., Roberts J.K. Dizziness, vertigo, and hearing loss. In: Rowland LP,Pedley TA, eds. Merritt's Neurology. 12th ed.
Philadelphia, PA: Lippinocott Williams& Wilkins; 2010:38–43.268. Tanaka A., Ueno Y., Nakayama Y., et al. Small chronic hemorrhages and125ischemic lesions in association with spontaneous intracerebral hematomas. Stroke.1999;30:1637–1642.269. Thomas A.J., Kalaria R.N., O'Brien J.T. Depression and vascular disease: whatis the relationship?. J Affect Disord. Apr 2004;79(1-3):81-95.270. Thomas T., Thomas G., McLendon C., et al. β-Amyloid- mediated vasoactivityand vascular endothelial damage. Nature.
1996;380:168–171.271. de la Torre J.C. Alzheimer Disease as a Vascular Disorder: NosologicalEvidence // Stroke. 2002. Vol.33 (4). P.1152-1162.272. Traccis S., Zoroddu G.F., Zecca M.T., et al. Evaluating patients with vertigo:bedside examination. Neurol Sci. 2004;25(suppl 1):S16–S19.273. Tzourio C., Dufouil C.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
